Piper Sandler Reiterates Rating on Tenax Therapeutics, Inc. $TENX
Key Points
- Piper Sandler now rates Tenax Therapeutics, Inc. ($TENX) "buy" with a $50.00 target.
- The Street's average $TENX price target is $34.00 (Strong Buy).
- $TENX last traded around $11.48.
Piper Sandler reiterated its rating on Tenax Therapeutics, Inc. ($TENX) to a "buy" rating, with a price target of $50.00 in a recent research note.
Tenax Therapeutics, Inc. ($TENX) Stock
Tenax Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.